MindMed has dosed the first subject in a Phase III study of MM120 tablets for the treatment of generalised anxiety disorder.

Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

PHOENIXVILLE, PA — Facet Life Sciences has been selected as the U.S. regulatory partner for Cybin Inc., a neuropsychiatry ...

Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...

(NASDAQ: MNMD), a biopharmaceutical company in the clinical stage with a market capitalization of $548.52 million, announced today that its experimental treatment for Generalized Anxiety Disorder ...

The guideline emphasizes the importance of establishing ... anticipatory anxiety, or comorbid disorders can persist. Educating the patient and the family may be of value, and it is occasionally ...

More than half of people with migraine also experience anxiety, but it's hard to say which comes first. Find out how the two ...

While people with Generalized Anxiety Disorder (GAD) are more prone to high-functioning anxiety, the latter is not a diagnosed mental health disorder. It is, instead, a catch-all term – however ...

A new guideline published today recommends chronic asthma should be diagnosed by healthcare professionals when people first show symptoms by using simple tests. The guideline also says healthcare ...